All Oncology News

Ruxolitinib met the primary endpoint of the phase III REACH2 trial, improving the overall response rate at day 28 versus best available therapy in patients with in patients with steroid-refractory acute graft-versus-host disease.

Gretchen G. Kimmick, MD, MS, discusses the management of patients with early-stage hormone receptor–positive, HER2-negative breast cancer.

Daria V. Babushok, MD, PhD, provides insight into the latest developments in the treatment of patients with benign hematologic malignancies.

Noelle Frey, MD, MS, highlights various therapies available to patients with acute lymphocytic leukemia and the importance of measuring minimal residual disease.

Combining the pegylated IL-10 pegilodecakin with FOLFOX (folinic acid, 5-FU, oxaliplatin) chemotherapy did not improve overall survival as a second-line therapy for patients with metastatic pancreatic cancer.

Alexander Edward Perl, MD, MS, discusses advancements in acute myeloid leukemia treatment and future approaches in the field.

Patients with metastatic gastric or gastroesophageal junction cancer had improved overall survival with TAS-102, irrespective of prior gastrectomy.

Michael Untch, MD, PhD, discusses the primary findings from the phase III KATHERINE trial and the added impact of long-term safety data regarding the use of adjuvant T-DM1 in early-stage HER2-positive breast cancer.

Faculty from Huntsman Cancer Institute and Intermountain Healthcare delve into the interesting research efforts being made at their respective institutions.

James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lymphocytic leukemia and other potentially practice-changing trials on the horizon.

Sunita Nasta, MD, discusses exciting updates in follicular lymphoma, diffuse large B-cell lymphoma, and T-cell lymphoma and the impact they will have on the upfront and relapsed/refractory paradigms.

Adam J. Waxman, MD, MS, discusses new and upcoming multiple myeloma treatments and how to optimally manage toxicities from these regimens.

Lisa A. Cannon-Albright, PhD, discusses her research regarding the heredity of lung cancer, histologic subgroups at increased risk, and the implications these data have on practice.

Ezzat Elhassadi, MD, discusses the results from a 10-year institutional analysis and how the presence of a TP53 mutation can correlate with survival outcomes in patients with mantle cell lymphoma.

Findings from the 2019 ESMO Congress showcased that biosimilars for pegfilgrastim, filgrastim, bevacizumab, and trastuzumab demonstrated efficacy and safety equivalency with their reference counterparts in a number of malignancies.

The UK’s National Institute for Health and Care Excellence has approved rucaparib for the maintenance treatment of patients with relapsed ovarian, fallopian tube, or peritoneal cancer that has responded to platinum-based chemotherapy.

Faculty from the George Washington Cancer Center to shed light on some of the current and future research efforts being made at their institution.

Kristen Champion, PhD, FACMG, discusses various molecular testing methods being used in non–small cell lung cancer.

Shiven B. Patel, MD, MBA, FACP, provides insight into key trials in squamous non–small cell lung cancer and how to apply the data to practice.

William T. Sause, MD, discusses various modalities of stage III non–small cell lung cancer treatment and how to effectively select patients for the varying regimens.

The trial, which received a $4.1 million in grants from the National Institutes of Health and Gateway for Cancer Research, combines City of Hope’s unique CAR T cell therapy with immune checkpoint inhibitors.

R. Steven Paulson, MD, discusses how to adapt to the era of precision medicine, the latest with liquid biopsies, and a unique diagnostic tool with the potential to revolutionize oncology.

Clarke A. Low, MD, discusses the role of osimertinib in EGFR-mutated non–small cell lung cancer and emerging research efforts in the paradigm.

William Eward, MD, DVM, discusses the use of pexidartinib and other options to treat patients with tenosynovial giant cell tumor, as well as future recommendations for the field, such as using comparative oncology when researching drugs.

Katie Kerrigan, MD, discusses novel agents emerging in both ROS1- and ALK-mutated non–small cell lung cancer and the sequencing challenges for these patients.

Imad Tabbara, MD, discusses the role of minimal residual disease testing in multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia, as well as emerging regimens in all 3 malignancies that are changing standards of care.

Wallace L. Akerley, MD, discusses targeted approaches for patients with non-small cell lung cancer who harbor alterations in MET, RET, and HER2, as well as the importance of broad molecular profiling.

Sonam Puri, MD, discusses key trials in metastatic nonsquamous disease and highlights ongoing research generating excitement in the space.

Kieron Dunleavy, MD, discusses emerging treatment options and when to use the watch-and-wait approach in follicular lymphoma.

Simon Rule, MD, discusses the standard of care for MCL treatment and future regimens that could transform clinical practice.